The Loophole, the Limits, and the Liability: Inside Florida’s New Stem Cell Law

One year after its July 1, 2025, effective date, Florida quietly became the largest state in the country to let licensed physicians administer stem cell therapies that the FDA has never approved. The vehicle was Senate Bill 1768, and it did not squeak through. It passed 37 to 0 in the Senate and 112 to 0 in the House, then became law without the governor's signature.

For most orthopedic and spine surgeons, this barely registered. It should. Although SB 1768 is a Florida law, it may become a national test case for how states regulate regenerative medicine. The law is built around the precise indications you treat every day: orthopedics, wound care, and pain management. Florida did not write a vague medical freedom statute. It aimed one straight at musculoskeletal medicine.

That makes the one-year mark worth watching nationally. Florida is not Utah, and it is not acting in isolation. Other states have begun carving out access to investigational stem cell or biologic therapies, but Florida has gone further by tying its law to physician scope, defined clinical categories, cGMP manufacturing, post-thaw viability reporting, and product documentation. In a state with one of the country’s largest musculoskeletal markets — arthritis, spine pain, sports injury, and chronic orthopedic disease — makes SB 1768 a national test case.

It is also not merely a loophole story. Chronic pain, longevity, mobility, and recovery are top of mind for more Americans than ever, and patients are already seeking stem cell and regenerative treatments through medical tourism, longevity clinics, chronic pain clinics, and direct-to-consumer offerings that vary widely in quality and documentation. Florida’s law is best understood as an attempt to put a physician-led framework around a market that has been operating for years with too little structure.

What SB 1768 Actually Does

In plain language, the law says a Florida MD or DO may perform a non-FDA-approved stem cell therapy, as long as it falls within the physician's scope of practice and is used for orthopedics, wound care, or pain management. Everything else can be seen as guardrails.

Who. Only physicians licensed under Chapter 458 (MDs) and Chapter 459 (DOs). No chiropractors, naturopaths, or independent mid-levels.

Sourcing. Cells must be processed by facilities registered with the FDA and accredited by a recognized body such as the American Association of Tissue Banks or the Association for the Advancement of Blood and Biotherapies. The facility must provide a post-thaw viability report, and providers must follow current good manufacturing practices.

Consent. Signed informed consent spelling out the therapy, its lack of FDA approval, the risks, and the alternatives, including doing nothing. Patients must be encouraged to consult their primary care provider.

Advertising. Any ad must carry a conspicuous notice that the therapy is not FDA approved, in type at least as large as the biggest font in the ad.

Hard limit. Cells derived from a fetus or embryo after an abortion are off limits, and using them is a third-degree felony. Additionally, systemic use is prohibited, meaning the statute permits localized, indication-specific injections rather than IV stem cell infusions.

What's Clear, and What Isn't

Start with what's clear. An orthopedic surgeon in Tampa can offer a stem cell injection for an arthritic knee using product from an accredited tissue bank, document consent, and stay inside the statute. The surgeon cannot use it to treat Parkinson's disease, cannot advertise without the disclaimer, and cannot touch post-abortion fetal tissue.

The murky part is the cells themselves. The statute leans toward adult-derived, ethically sourced material and points to birth tissue such as umbilical cord blood, but it is not a tidy list of approved cell types. That does not mean every product already marketed as “stem cells” fits the framework. In practice, the law may push some current offerings out of bounds while creating a pathway for products designed to align with its requirements, including bone marrow-derived products and compliant versions of perinatal products. Reasonable readers disagree about whether common products like adipose-derived preparations and exosomes are in or out. When the people who do this for a living cannot agree on what counts as an allowed source, that is your signal that the ground is soft, and right now that ambiguity is being resolved clinic by clinic rather than by any line in the statute.

That product-level question may define the next year. Florida does not simply legalize everything already being sold as “stem cells.” It puts pressure on suppliers to show that a product was built for this framework, with traceable sourcing, cGMP processing, lot-level documentation, post-thaw viability, validated handling, localized intended use, and disciplined claims.

“Orthopedic physicians do not need more hype around stem cells; they want products that are as effective, safe, and consistent as they and their patients expect” said Priya Chordia, founder of TAVRA Biosciences, a company developing an adult-derived bone marrow cell product for physician-directed orthopedic and pain applications. “The question should not be whether a product is legal. The question should be whether it is produced in accordance with best practices to ensure it is what it claims to be.”

The Federal-State Collision

SB 1768 is in direct conflict with federal law, and when the two collide, federal law wins. The Federal Food, Drug, and Cosmetic Act (FDCA) requires that a cell or tissue product marketed to treat a condition like joint pain or a wound carry FDA approval, typically a Biologics License Application, unless it is minimally manipulated and used for the same basic function it serves in the body. Most of what gets marketed as orthopedic "stem cell therapy" does not clear that bar.

Florida cannot waive a federal requirement. A state can decline to prosecute under its own statutes, but it cannot immunize a physician from the FDCA. There is even a wrinkle inside Florida's own law: the state's Drug and Cosmetic Act treats a violation of federal law as a violation of state law, which puts SB 1768 crosswise with another Florida statute already on the books.

And this is no longer theoretical. In September 2024, the Ninth Circuit ruled in United States v. California Stem Cell Treatment Center that a clinic's stromal vascular fraction product, the fat-derived preparation marketed all across the regenerative world, is a drug subject to FDA premarket approval. That put three federal circuits in agreement. In October 2025, the Supreme Court declined to hear the appeal, leaving the ruling in place. A surgeon operating under SB 1768 is, in effect, betting the FDA will not come knocking. That bet may pay off for a long while. It is still a bet. And the protection is essentially in-state: the moment a product crosses a state line, it is back in interstate commerce and squarely under federal jurisdiction.

Florida Is Not Alone

Florida is the biggest domino, but not the first. Utah, in 2024, authorized non-FDA-approved placental and perinatal therapies. Texas, Mississippi, and North Carolina passed earlier right-to-try-style laws for serious, chronic, or terminal illness. The pattern is unmistakable: legislatures, responding to patient demand and frustration with a slow, expensive federal pathway, are carving out their own lanes. Florida's is the most consequential because of its size, demographics, and orthopedic focus. If it stands, expect more states to follow, and expect the next bills to test whether the allowed indications can be widened.

The Bigger Question

The honest way to frame Florida is as an experiment, and the cleanest analogy is cannabis. A state has greenlit an activity the federal government still considers illegal. For now the two systems coexist in an uneasy truce, held together by prosecutorial discretion and political will, not by any real resolution of the conflict. Cannabis taught us that arrangement can persist for years. It also taught us that the people operating in the gap carry real risk the whole time, and that the rules can change with an election or a single court decision.

Stem cells in Florida are now in that gap. The science will keep advancing. Patient demand, especially among Florida's older population, will keep rising. But whether SB 1768 becomes a model or a cautionary tale will depend not only on what the FDA, the courts, and the next legislature decide to do about it. It will also depend on whether physicians and suppliers use the law to clean up the market rather than expand its worst habits. For orthopedic surgeons, who sit at the center of the indications this law covers, that is the reason to watch Florida now.